Top Stories
Despite the negative market reaction, Cue says it is advancing CUE-221 into a Phase IIb/III study in chronic spontaneous urticaria and in a Phase II food allergy study.
ADARx is also likely to raise an additional $80 million in a private placement from AbbVie.
Phase III data show the experimental cagrilintide and semaglutide combo can outperform a lower-dose of Lilly's Zepbound on weight loss in people with type 2 diabetes.
Shares fell more than 5% as the company detailed plans to revive fortunes in the obesity drug market and diversify beyond its key areas.
Deal adds late-stage asset ITM-11 to Telix’s portfolio, while also establishing a vertically integrated radiopharmaceutical entity.
Conference News
Early Data for T-MAXIMUM's B7-H3 Allogeneic CAR-T in Brain Metastases Presented at WCLC 2026BEIJING, Sept. 21, 2026 /PRNewswire/ -- As B7-H3 ADCs reshape the second-line treatment landscape for small ...
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tar...
NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb stu...
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential SymposiumModerna to host an investor event vi...
Presentations will highlight Phase 2b OPTI-2 findings demonstrating the potential of HDV-insulin lispro to maintain glycemic control while reducing hypoglycemia in adults with type 1 diabetesNew expos...
